Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Protective association of angiotensin blockade with influenza: A result of immortal time bias?

    Research output: Contribution to journalLetterResearchpeer-review

  3. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  • E F Magavern
  • J C Kaski
  • R M Turner
  • H Drexel
  • A Janmohamed
  • A Scourfield
  • D Burrage
  • C N Floyd
  • E Adeyeye
  • J Tamargo
  • B S Lewis
  • Keld Per Kjeldsen
  • A Niessner
  • S Wassmann
  • P Sulzgruber
  • P Borry
  • S Agewall
  • A G Semb
  • G Savarese
  • M Pirmohamed
  • M J Caulfield
View graph of relations

Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on PGx implementation. Clinical work force upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

Original languageEnglish
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Publication statusE-pub ahead of print - 31 Aug 2021

ID: 67446039